Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003

Published Date:

August 8, 2003

Status:

current

Source:

MMWR. Morbidity and mortality weekly report. 2003; 52(31):735-9.

Language:

English

[PDF-260.70 KB]

Details:

Corporate Authors:

Centers for Disease Control and Prevention (U.S.) ; American Thoracic Society. ;

Description:

A previously published report provided guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis (TB). Protease inhibitors and NNRTIs are antiretroviral agents that are substrates that may inhibit or induce cytochrome P-450 isoenzymes (CYP450). Rifamycins are antituberculosis agents that induce CYP450 and may decrease substantially blood levels of the antiretroviral drugs. The pharmacologic interactions are called drug-drug because, in addition to the effect rifamycins have on protease inhibitors and NNRTIs, the antiretroviral agents may affect the blood levels of rifamycins. This notice presents updated data pertaining to drug-drug interactions between these agents and recommendations for their use from a group of CDC scientists and outside expert consultants.

Subject:

[+]

Pubmed ID:

12904741

Document Type:

Journal Article

Place as Subject:

United States

Collection(s):

Advisory Committee on Immunization Practices (ACIP)
Guidelines and Recommendations

Main Document Checksum:

[+]

Supporting Files:

No Additional Files

No Related Documents.

You May Also Like:

MMWR. Morbidity and mortality weekly report, Vol. 52, no. 31, August 8, 2003

Corporate Authors:

Centers for Disease Control and Prevention (U.S.)

Published Date:

August 8, 2003

Series:

MMWR. Morbidity and mortality weekly report ; v. 52, no. 31

File Type:

[PDF - 587.17 KB]
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020

Personal Author:

Sterling, Timothy R.; Njie, Gibril; Zenner, Dominik; Cohn, David L.; Reves, Randall; Ahmed, Amina; Menzies, Dick; Horsburgh, C. Robert; Crane, Charles M.; Burgos, Marcos; LoBue, Philip; Winston, Carla A.; Belknap, Robert;

Corporate Authors:

National Tuberculosis Controllers Association.. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination..

Published Date:

February 14 2020

Source:

MMWR Recomm Rep. 69(1):1-11

Description:

Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among persons living in the United States were last published in 2000 (American Thoracic Society. CDC targeted tuberculin testing and treatment of latent tuberculosis infe...

Status:

current

File Type:

[PDF - 337.36 KB]
TB facts for health care workers 2006

Corporate Authors:

National Center for HIV, STD, and TB Prevention (U.S.), Division of Tuberculosis Elimination.

Published Date:

2006

Description:

Selected bibliography: p. 21-23.

File Type:

[PDF - 1.20 MB]
Pneumococcal vaccination for cochlear implant candidates and recipients : updated recommendations of the Advisory Committee on Immunization Practices.

Corporate Authors:

United States. Advisory Committee on Immunization Practices.. Centers for Disease Control and Prevention (U.S.).

Published Date:

August 8, 2003

Source:

MMWR. Morbidity and mortality weekly report. 2003; 52(31):739-40.

Description:

In October 2002, CDC recommended that all persons with cochlear implants receive age-appropriate pneumococcal vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) (Prevnar), 23-valent pneumococcal polysaccharide vaccine (PPV23) (Pneumovax)...

Status:

superseded

File Type:

[PDF - 587.17 KB]
Treatment of latent tuberculosis infection and tuberculosis disease

Corporate Authors:

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.

Published Date:

2019

Series:

Self-study modules on tuberculosis ; module 4

Description:

Course #WB2556In this module, you will learn about the principles of treating latent TB infection (LTBI) and TB disease. A person with LTBI is treated to prevent them from progressing to TB disease. Some people with LTBI are at very high risk of deve...

File Type:

[PDF - 8.62 MB]